KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Gastric Cancer|Breast Cancer|Cervical Cancer|Lung Cancer
Interventions: DRUG: KK-LC-1 TCR-T cells|DRUG: Aldesleukin 720,000 IU/kg IV every eight hours
Sponsor: Christian Hinrichs
Collaborators: Cancer Immunology and Metabolism Center of Excellence at Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)